Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin

Drug Metabolism and Disposition

Volumn 36, Issue 8, 2008, Pages 1624-1636

  Lu, Wei ^a,b   Uetrecht, Jack P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYCARBAMAZEPINE; 3 HYDROXYCARBAMAZEPINE; 4 HYDROXYPHENYTOIN; CARBAMAZEPINE; DRUG METABOLITE; FREE RADICAL; MYELOPEROXIDASE; N ACETYLTYROSINE; PEROXIDASE; PHENYTOIN; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIMERIZATION; DRUG ACTIVATION; DRUG HYDROXYLATION; DRUG INDUCED DISEASE; DRUG METABOLISM; HUMAN; IDIOSYNCRATIC DRUG REACTION; MOUSE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; OXIDATION KINETICS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICONVULSANTS; BIOTRANSFORMATION; CARBAMAZEPINE; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIMERIZATION; HORSERADISH PEROXIDASE; HYDROXYLATION; MAGNETIC RESONANCE SPECTROSCOPY; MICE; OXIDATIVE STRESS; PEROXIDASE; PHENYTOIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 45849146846     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.019554     Document Type: Article

References (39)

1. Askmark H and Wiholm BE (1990) Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 81:131-140.
2. Bernus I, Dickinson RG, Hooper WD, and Eadie MJ (1996) Dose-dependent metabolism of carbamazepine in humans. Epilepsy Res 24:163-172.
3. Brown KE, Brunt EM, and Heinecke JW (2001) Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver. Am J Pathol 159:2081-2088.
4. Bruno JG, Herman TS, Cano VL, Stribling L, and Kiel JL (1999) Selective cytotoxicity of 3-amino-L-tyrosine correlates with peroxidase activity. In Vitro Cell Dev Biol Anim 35:376-382.
5. Bu HZ, Kang P, Deese AJ, Zhao P, and Pool WF (2005) Human in vitro glutathionyl and protein adducts of carbamazepine-10,11-epoxide, a stable and pharmacologically active metabolite of carbamazepine. Drug Metab Dispos 33:1920-1924.
6. Chow SA, Charkowski DM, and Fischer LJ (1980) Separation of phenytoin and its metabolites by high-performance liquid chromatography. Life Sci 27:2477-24820.
7. Furst SM and Uetrecht JP (1993) Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem Pharmacol 45:1267-1275.
8. Furst SM and Uetrecht JP (1995) The effect of carbamazepine and its reactive metabolite, 9-acridine carboxaldehyde, on immune cell function in vitro. Int J Immunopharmacol 17:445-452.
9. Gaedigk A, Spielberg SP, and Grant DM (1994) Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 4:142-153.
10. Garle MJ, Knight A, Downing AT, Jassi KL, Clothier RH, and Fry JR (2000) Stimulation of dichlorofluorescin oxidation by capsaicin and analogues in RAW 264 monocyte/macrophages: lack of involvement of the vanilloid receptor. Biochem Pharmacol 59:563-572.
11. Green VJ, Pirmohamed M, Kitteringham NR, Gaedigk A, Grant DM, Boxer M, Burchell B, and Park BK (1995) Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol 50:1353-1359.
12. Hart RG and Easton JD (1982) Carbamazepine and hematological monitoring. Ann Neurol 11:309-312.
13. Haruda F (1979) Phenytoin hypersensitivity: 38 cases. Neurology 29:1480-1485.
14. Heinecke JW (2002) Tyrosyl radical production by myeloperoxidase: a phagocyte pathway for lipid peroxidation and dityrosine cross-linking of proteins. Toxicology 177:11-22.
15. Heinecke JW, Li W, Daehnke HL, 3rd, and Goldstein JA (1993) Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem 268:4069-4077.
16. Hussain A, Trudell P, and Repta AJ (1970) Quantitative spectrophotometric methods for determination of sodium hypochloride in aqueous solutions. J Pharm Sci 59:1168-1170.
17. Hyson C and Sadler M (1997) Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci 24:245-249.
18. Joffe RT, Post RM, Roy-Byrne PP, and Uhde TW (1985) Hematological effects of carbamazepine in patients with affective illness. Am J Psychiatry 142:1196-1199.
19. Jorgensen TK, Andersen KE, Lau J, Madsen P, and Huusfeldt PO (1999) Synthesis of substituted 10,11-dihydro-5H-dibenz[b,f]azepines; key synthons in synthesis of pharmacologically active compounds. J Heterocyclic Chem 36:57-64.
20. Ju C and Uetrecht JP (1999) Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J Pharmacol Exp Ther 288:51-56.
21. Leeder JS (1998) Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 39:S8-S16.
22. Leeder JS, X Lu, Y Timsit, and A Gaedigk (1998) Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions. Pharmacogenetics 8:211-225.
23. Lertratanangkoon K and Horning MG (1982) Metabolism of carbamazepine. Drug Metab Dispos 10:1-10.
24. Malencik DA, Sprouse JF, Swanson CA, and Anderson SR (1996) Dityrosine: preparation, isolation, and analysis. Anal Biochem 242:202-213.
25. Moldeus P, Hogberg J, and Orrenius S (1978) Isolation and use of liver cells. Methods Enzymol 52:60-71.
26. Moridani MY, Scobie H, Jamshidzadeh A, Salehi P, and O'Brien PJ (2001) Caffeic acid, chlorogenic acid, and dihydrocaffeic acid metabolism: glutathione conjugate formation. Drug Metab Dispos 29:1432-1439.
27. Munns AJ, De Voss JJ, Hooper WD, Dickinson RG, and Gillam EM (1997) Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation. Chem Res Toxicol 10:1049-1058.
28. Oshino N, Jamieson D, and Chance B (1975) The properties of hydrogen peroxide production under hyperoxic and hypoxic conditions of perfused rat liver. Biochem J 146:53-65.
29. Pantarotto C, Arboix M, Sezzano P, and Abbruzzi R (1982) Studies on 5,5-diphenylhydantoin irreversible binding to rat liver microsomal proteins. Biochem Pharmacol 31:1501-1507.
30. Park BK, Pirmohamed M, and Kitteringham NR (1995) The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 68:385-424.
31. Parman T, Chen G, and Wells PG (1998) Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry, and photochemical product analysis. J Biol Chem 273:25079-25088.
32. Pearce RE, Uetrecht JP, and Leeder JS (2005) Pathways of carbamazepine bioactivation in vitro II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos 33:1819-1826.
33. Shear NH and SP Spielberg (1988) Anticonvulsant hypersensitivity syndrome. J Clin Invest 82:1826-1832.
34. Spielberg SP, Gordon GB, Blake DA, Goldstein DA, and Herlong HF (1981) Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 305:722-727.
35. Turner P (1960) Granulocytopenia after treatment with phenytoin sodium. Br Med J 1:1790.
36. Uetrecht J and Zahid N (1988) N-Chlorination of phenytoin by myeloperoxidase to a reactive metabolite. Chem Res Toxicol 1:148-151.
37. Vittorio CC and Muglia JJ (1995) Anticonvulsant hypersensitivity syndrome. Arch Intern Med 155:2285-2290.
38. Yamazaki H, Komatsu T, Takemoto K, Saeki M, Minami Y, Kawaguchi Y, Shimada N, Nakajima M, and Yokoi T (2001) Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats. Drug Metab Dispos 29:427-434.
39. Zeng J and Fenna RE (1992) X-ray crystal structure of canine myeloperoxidase at 3 A resolution. J Mol Biol 226:185-207.